Reading HBIO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HBIO free→
Harvard Bioscience Inc (HBIO)
NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-15
Intact
$5.99-1.48%
Close 2026-06-15 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 82% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak or earnings quality is fragile. If HBIO cuts guidance on the next call, that's a meaningful negative. This read is provisional.
as of 2026-06-15
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Medical Instruments & Supplies
- Market cap
- $27.42M
- Employees
- —
- IPO date
- 2000-09-18
- Next earnings
- 2026-08-10
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $5.99. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryinexpensive
$33.59consensus
Range $21.82 – $45.37
vs price: -82% below
Method agreement — · 2 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$24.76consensus
Range $14.49 – $35.04
vs price: -76% below
Method agreement — · 2 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Cheap vs peerslow confidence
At $5.99 HBIO trades at 0× p/s, below its 3× p/s peer median. Our $33 fair value sits above the price; low confidence. Not investment advice.
Multiple (P/S)
0.3x
peer 2.8x · own history —
Premium
0.1x peer
Growth the price needs
-82%
our forecast -5%
Our fair value
$33.41
range $21.66 – $45.16
WhyEarnings too small for P/EPeer anchor overstates the discount
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
inexpensivecheap — value-trap risk12-month view
What's priced inJustified
The price implies about 82% below a flat-multiple fair value, below our forecast of about -5%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Low fragilityrisk posture, not a price call
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
75th pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted -0.31x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
volatileEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bullish2 analysts, 50% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $0.00 → $-0.21. 1 raised, 0 cut, 2 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 50% of analysts rate Buy.
Material events
0 positive, 0 negative / 30d.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
Sector context
Intermediate · WeeklySector phase: health care is in (~0.5 years in phase).
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: weak
- Capital allocation
- weak
- Earnings discipline
- weak
- Margin discipline
- weak
- Balance sheet
- neutral
- Post-call reaction
- strong
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$303.
How much price usually moves either way.
On a bad day, this stock has moved -$693.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,524.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-15
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideMedium confidenceMonthsactive 4d
Watch for revenue growth speeding up in the sector.
Why it matters: If the health care sector's revenue growth speeds up, it could help Harvard Bioscience. This would signal a better environment for the company.
What confirms / what disproves
Confirms:Health care sector revenue growth returns to near 10 percent or higher.
Disproves:The health care sector's revenue growth is slowing down. It is below current levels.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for HBIO yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ISRG, MDLN, and BDX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting HBIO and other Healthcare names. Worth watching these names for early signals.
- If HBIO raises forward guidance on the next earnings call (currently NEW as of 2026-05-12), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
- If HBIO beats again next quarter like it did this past one (a solid beat of +19% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
Downside triggers
- If HBIO cuts guidance on the next call (currently NEW as of 2026-05-12), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like ISRG, MDLN, and BDX start missing or guiding lower, the Healthcare tailwind helping HBIO and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-0215d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 2, 2026, the stockholders of Harvard Bioscience, Inc. (the “ Company ”) voted to approve the Amended and Restated 2021 Incentive Plan at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The principal modification to the Amended and Restated 2021 Incentive Plan is to increase the number of authorized shares of the Co…
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-3.1 vs last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.